{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T10:31:56Z","timestamp":1760783516192},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2012,3,13]],"date-time":"2012-03-13T00:00:00Z","timestamp":1331596800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Hematol Malig Rep"],"published-print":{"date-parts":[[2012,6]]},"DOI":"10.1007\/s11899-012-0117-2","type":"journal-article","created":{"date-parts":[[2012,3,12]],"date-time":"2012-03-12T07:15:53Z","timestamp":1331536553000},"page":"103-108","source":"Crossref","is-referenced-by-count":21,"title":["Curing Chronic Myeloid Leukemia"],"prefix":"10.1007","volume":"7","author":[{"given":"Delphine","family":"Rea","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philippe","family":"Rousselot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joelle","family":"Guilhot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fran\u00e7ois","family":"Guilhot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fran\u00e7ois-Xavier","family":"Mahon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2012,3,13]]},"reference":[{"key":"117_CR1","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1182\/blood.V92.5.1541","volume":"92","author":"Italian Cooperative Study Group on Chronic Myeloid Leukemia","year":"1998","unstructured":"Italian Cooperative Study Group on Chronic Myeloid Leukemia. Long-term follow-up of the Italian trial of interferon-\u03b1 versus conventional chemotherapy in chronic myeloid leukemia. Blood. 1998;92:1541\u20138.","journal-title":"Blood"},{"key":"117_CR2","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1056\/NEJMoa022457","volume":"348","author":"SG O\u2019Brien","year":"2003","unstructured":"\u2022 O\u2019Brien SG, Guilhot F, Larson RA, et al.: Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. New Engl J Med 2003, 348:994-1004. This study shows that imatinib is superior to previous treatment option interferon plus cytarabine as first-line therapy in patients with newly diagnosed CP-CML.","journal-title":"New Engl J Med"},{"key":"117_CR3","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1182\/blood-2006-02-001495","volume":"108","author":"L Roy","year":"2006","unstructured":"Roy L, Guilhot J, Krahnke T, et al. Survival advantage from imatinib compared with the combination interferon-alpha plus cytarabine in chronic-phase chronic myelogenous leukemia: historical comparison between two phase 3 trials. Blood. 2006;108:1478\u201384.","journal-title":"Blood"},{"key":"117_CR4","doi-asserted-by":"crossref","first-page":"6041","DOI":"10.1200\/JCO.2009.25.0779","volume":"27","author":"M Baccarani","year":"2009","unstructured":"Baccarani M, Cortes J, Pane F, et al. Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. J Clin Oncol. 2009;27:6041\u201351.","journal-title":"J Clin Oncol"},{"key":"117_CR5","doi-asserted-by":"crossref","first-page":"3204","DOI":"10.1200\/JCO.2007.14.9260","volume":"26","author":"NP Shah","year":"2008","unstructured":"Shah NP, Kantarjian HM, Kim DW, et al. Intermittent target inhibition with dasatinib 100\u00a0mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia. J Clin Oncol. 2008;26:3204\u201312.","journal-title":"J Clin Oncol"},{"key":"117_CR6","doi-asserted-by":"crossref","first-page":"3540","DOI":"10.1182\/blood-2007-03-080689","volume":"110","author":"HM Kantarjian","year":"2007","unstructured":"Kantarjian HM, Giles F, Gattermann N, et al. Nilotinib (formerly AMN107), a highly selective BCR-ABL inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance. Blood. 2007;110:3540\u20136.","journal-title":"Blood"},{"key":"117_CR7","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1056\/NEJMoa1002315","volume":"362","author":"H Kantarjian","year":"2010","unstructured":"Kantarjian H, Shah NP, Hochhaus A, et al. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. New Eng J Med. 2010;362:2260\u201370.","journal-title":"New Eng J Med"},{"key":"117_CR8","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1056\/NEJMoa0912614","volume":"362","author":"G Saglio","year":"2010","unstructured":"Saglio G, Kim D-W, Issaragrisil S, et al. Nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia. New Eng J Med. 2010;362:2251\u20139.","journal-title":"New Eng J Med"},{"key":"117_CR9","first-page":"109","volume":"118","author":"JE Cortes","year":"2011","unstructured":"Cortes JE, Kim D-W, Pinilla-Ibarz J, et al. Initial findings from the PACE trial: a pivotal phase 2 study of ponatinib in patients with CML and Ph+ ALL resistant or intolerant to dasatinib or nilotinib, or with the T315I mutation. Blood (ASH annual Meeting Abstracts). 2011;118:109.","journal-title":"Blood (ASH annual Meeting Abstracts)"},{"key":"117_CR10","doi-asserted-by":"crossref","first-page":"2514","DOI":"10.1200\/JCO.2011.34.7146","volume":"29","author":"M Bj\u00f6rkholm","year":"2011","unstructured":"Bj\u00f6rkholm M, Ohm L, Eloranta S, et al. Success story of targeted therapy in chronic myeloid leukemia: a population-based study of patients diagnosed in Sweden from 1973 to 2008. J Clin Oncol. 2011;29:2514\u201320.","journal-title":"J Clin Oncol"},{"key":"117_CR11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/10428190500407996","volume":"47","author":"J Goldman","year":"2006","unstructured":"Goldman J, Gordon M. Why do chronic myelogenous leukemia stem cells survive allogeneic stem cell transplantation or imatinib: does it really matter? Leuk Lymphoma. 2006;47:1\u20137.","journal-title":"Leuk Lymphoma"},{"key":"117_CR12","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1038\/sj.bmt.1700933","volume":"20","author":"F Rhee Van","year":"1997","unstructured":"Van Rhee F, Szydlo RM, Hermans J, et al. Long term results after allogeneic transplantation for chronic myelogenous leukemia in chronic phase: a report from the chronic leukemia working party of the European group for blood and marrow transplantation. Bone Marrow Transplant. 1997;20:553\u201360.","journal-title":"Bone Marrow Transplant"},{"key":"117_CR13","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1182\/blood-2010-08-301341","volume":"117","author":"J Pavlu","year":"2011","unstructured":"Pavlu J, Szydlo R, Goldman JM, Apperley JF. Three decades of transplantation for chronic myeloid leukemia: what have we learned? Blood. 2011;117:755\u201363.","journal-title":"Blood"},{"key":"117_CR14","doi-asserted-by":"crossref","first-page":"4171","DOI":"10.1182\/blood-2005-08-3320","volume":"107","author":"J Kaeda","year":"2006","unstructured":"Kaeda J, O\u2019Shea D, Szydlo RM, et al. Serial measurement of BCR-ABL transcripts in the peripheral blood after allogeneic stem cell transplantation for chronic myeloid leukemia: an attempt to define patients who may not require further therapy. Blood. 2006;107:4171\u20136.","journal-title":"Blood"},{"key":"117_CR15","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1182\/blood.V98.6.1701","volume":"98","author":"JP Radich","year":"2001","unstructured":"Radich JP, Gooley T, Bryant E, et al. The significance of bcr-abl molecular detection in chronic myeloid leukemia patients \u201clate\u201d, 18\u00a0months or more after transplantation. Blood. 2001;98:1701\u20137.","journal-title":"Blood"},{"key":"117_CR16","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1200\/JCO.20.1.214","volume":"20","author":"FX Mahon","year":"2001","unstructured":"Mahon FX, Delbrel X, Cony-Makhoul P, et al. Follow-up of complete cytogenetic remission in patients with chronic myeloid leukemia after cessation of interferon alfa. J Clin Oncol. 2001;20:214\u201320.","journal-title":"J Clin Oncol"},{"key":"117_CR17","doi-asserted-by":"crossref","first-page":"3758","DOI":"10.1182\/blood-2010-03-273979","volume":"116","author":"TP Hughes","year":"2010","unstructured":"Hughes TP, Hochhaus A, Branford S, et al. Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS). Blood. 2010;116:3758\u201365.","journal-title":"Blood"},{"key":"117_CR18","doi-asserted-by":"crossref","first-page":"2204","DOI":"10.1182\/blood-2004-04-1335","volume":"104","author":"J Cortes","year":"2004","unstructured":"Cortes J, O\u2019Brien S, Kantarjian H. Discontinuation of imatinib therapy after achieving a molecular response. Blood. 2004;104:2204\u20135.","journal-title":"Blood"},{"key":"117_CR19","doi-asserted-by":"crossref","first-page":"S71","DOI":"10.1016\/j.leukres.2003.10.017","volume":"28S1","author":"MJ Mauro","year":"2004","unstructured":"Mauro MJ, Druker BJ, Marziaz RT. Divergent clinical outcome in twp CML patients who discontinued imatinib therapy after achieving a molecular remission. Leuk Res. 2004;28S1:S71\u20133.","journal-title":"Leuk Res"},{"key":"117_CR20","first-page":"979","volume":"90","author":"S Merante","year":"2005","unstructured":"Merante S, Orlandi E, Bernasconi P, et al. Outcome of four patients with chronic myeloid leukemia after imatinib mesylate discontinuation. Haematologica. 2005;90:979\u201381.","journal-title":"Haematologica"},{"key":"117_CR21","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1016\/j.leukres.2008.11.027","volume":"33","author":"S Guastafierro","year":"2009","unstructured":"Guastafierro S, Falcone U, Celentano M, et al. Is it possible to discontinue imatinib mesylate therapy in chronic myeloid leukemia patients with undetectable BCR\/ABL? A case report and a review of the literature. Leuk Res. 2009;33:1079\u201381.","journal-title":"Leuk Res"},{"key":"117_CR22","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1182\/blood-2006-03-011239","volume":"109","author":"P Rousselot","year":"2007","unstructured":"Rousselot P, Huguet F, Rea D, et al. Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2\u00a0years. Blood. 2007;109:58\u201360.","journal-title":"Blood"},{"key":"117_CR23","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/S1470-2045(10)70233-3","volume":"11","author":"FX Mahon","year":"2010","unstructured":"\u2022\u2022 Mahon FX, Rea D, Guilhot J, et al.: Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2\u00a0years: the prospective, multicentre, Stop IMatinib (STIM) trial. Lancet Oncol. 2010, 11:1029-1035. STIM is the first large-scale clinical trial which has addressed the feasibility of imatinib discontinuation in patients with long-lasting undetectable BCR-ABL transcripts.","journal-title":"Lancet Oncol"},{"key":"117_CR24","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1038\/leu.2010.185","volume":"24","author":"DM Ross","year":"2010","unstructured":"\u2022 Ross DM, Branford S, Seymour JF, et al.: Patients with chronic myeloid leukemia who maintain a complete molecular response after stopping imatinib treatment have evidence of persistent leukemia by DNA PCR. Leukemia 2010, 24:1719-1724. This study shows that most patients with undetectable BCR-ABL transcripts on imatinib have detectable BCR-ABL DNA, even those who discontinue imatinib and do not need to resume therapy, suggesting that treatment discontinuation does not require leukemic cell eradication.","journal-title":"Leukemia"},{"key":"117_CR25","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1038\/leu.2008.376","volume":"23","author":"D Rea","year":"2009","unstructured":"Rea D, Raffoux E, Cayuela JM, et al. Sustained major molecular response in the absence of any antileukaemic therapy after dasatinib treatment and autologous peripheral blood stem cell transplantation in a patient with imatinib-resistant myeloblastic-phase chronic myeloid leukaemia. Leukemia. 2009;23:1158\u20139.","journal-title":"Leukemia"},{"key":"117_CR26","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.3324\/haematol.2011.048165","volume":"96","author":"DM Ross","year":"2011","unstructured":"Ross DM, Bartley PA, Goyne J, et al. Durable complete molecular remission of chronic myeloid leukemia following dasatinib cessation, despite adverse disease features. Haematologica. 2011;96:1720\u20132.","journal-title":"Haematologica"},{"key":"117_CR27","first-page":"604","volume":"118","author":"D Rea","year":"2011","unstructured":"Rea D, Rousselot P, Nicolini FE, et al. Discontinuation of dasatinib or nilotinib in chronic myeloid leukemia patients with stable undetectable Bcr-Abl transcripts: results from the French CML group (FILMC). Blood (ASH Annual Meeting Abstracts). 2011;118:604.","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"117_CR28","doi-asserted-by":"crossref","first-page":"3657","DOI":"10.1182\/blood-2011-02-335497","volume":"118","author":"J-C Chomel","year":"2011","unstructured":"Chomel J-C, Bonnet M-L, Sorel N, et al. Leukemic stem cell persistence in chronic myeloid leukemia patients with sustained undetectable molecular residual disease. Blood. 2011;118:3657\u201360.","journal-title":"Blood"},{"key":"117_CR29","first-page":"603","volume":"118","author":"F-X Mahon","year":"2011","unstructured":"Mahon F-X, Rea D, Guilhot J, et al. Discontinuation of imatinib in patients with chronic myeloid leukemia who have maintained complete molecular response: update results of the STIM study. Blood (ASH Annual Meeting Abstracts). 2011;118:603.","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"117_CR30","doi-asserted-by":"crossref","first-page":"3362","DOI":"10.1182\/blood.V92.9.3362","volume":"92","author":"S Bose","year":"1998","unstructured":"Bose S, Deininger M, Gora-Tybor J, et al. The presence of typical and atypical BCR-ABL fusion genes in leukocytes of normal individuals: biologic significance and implications for the assessment of minimal residual disease. Blood. 1998;92:3362\u20137.","journal-title":"Blood"},{"key":"117_CR31","first-page":"606","volume":"118","author":"TP Hughes","year":"2011","unstructured":"Hughes TP, Lipton JH, Leber B, et al. Complete molecular response (CMR) rate with nilotinib in patients with chronic myeloid leukemia in chronic phase without CMR \u2265 2\u00a0years on imatinib: preliminary results from the randomized ENESTcmr trial of nilotinib 400\u00a0mg twice daily (BID) vs imatinib. Blood (ASH Annual Meeting Abstracts). 2011;118:606.","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"117_CR32","doi-asserted-by":"crossref","first-page":"5565","DOI":"10.1182\/blood-2010-12-327437","volume":"118","author":"S Chu","year":"2011","unstructured":"Chu S, McDonald T, Lin A, et al. Persistence of leukemia stem cells in chronic myelogenous leukemia patients in prolonged remission with imatinib treatment. Blood. 2011;118:5565\u201372.","journal-title":"Blood"},{"key":"117_CR33","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1182\/blood.V99.1.319","volume":"99","author":"SM Graham","year":"2002","unstructured":"Graham SM, Jorgensen HG, Allan E, et al. Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro. Blood. 2002;99:319\u201325.","journal-title":"Blood"},{"key":"117_CR34","doi-asserted-by":"crossref","first-page":"4532","DOI":"10.1182\/blood-2005-07-2947","volume":"107","author":"M Copland","year":"2006","unstructured":"Copland M, Hamilton A, Elrick LJ, et al. Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction. Blood. 2006;107:4532\u20139.","journal-title":"Blood"},{"key":"117_CR35","doi-asserted-by":"crossref","first-page":"4016","DOI":"10.1182\/blood-2006-11-057521","volume":"109","author":"HG Jorgensen","year":"2007","unstructured":"Jorgensen HG, Allan EK, Jordanides NE, et al. Nilotinib exerts equipotent antiproliferative effects to imatinib and does not induce apoptosis in CD34+ CML cells. Blood. 2007;109:4016\u20139.","journal-title":"Blood"},{"key":"117_CR36","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1172\/JCI35721","volume":"121","author":"AS Corbin","year":"2011","unstructured":"Corbin AS, Agarwal A, Loriaux M, et al. Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity. J Clin Invest. 2011;121:396\u2013409.","journal-title":"J Clin Invest"},{"key":"117_CR37","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1182\/blood-2010-12-326843","volume":"119","author":"A Hamilton","year":"2012","unstructured":"Hamilton A, Helgason GV, Schemionek M, et al. Chronic myeloid leukemia stem cells are not dependent on Bcr-Abl kinase activity for their survival. Blood. 2012;119:1501\u201310.","journal-title":"Blood"},{"key":"117_CR38","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1016\/j.bcp.2010.04.003","volume":"80","author":"RR Nair","year":"2010","unstructured":"Nair RR, Tolentino J, Hazlehurst LA. The bone marrow microenvironment as a sanctuary for minimal residual disease in CML. Biochem Pharmacol. 2010;80:602\u201312.","journal-title":"Biochem Pharmacol"},{"key":"117_CR39","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1200\/JCO.2010.31.0904","volume":"29","author":"MY Konopleva","year":"2011","unstructured":"Konopleva MY, Jordan CT. Leukemia stem cells and microenvironment: biology and therapeutic targeting. J Clin Oncol. 2011;29:591\u20139.","journal-title":"J Clin Oncol"},{"key":"117_CR40","doi-asserted-by":"crossref","first-page":"5191","DOI":"10.1182\/blood-2008-08-176016","volume":"114","author":"RM Lemoli","year":"2009","unstructured":"Lemoli RM, Salvestrini V, Bianchi E, et al. Molecular and functional analysis of the stem cell compartment of chronic myelogenous leukemia reveals the presence of a CD34- cell population with intrinsic resistance to imatinib. Blood. 2009;114:5191\u2013200.","journal-title":"Blood"},{"key":"117_CR41","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1038\/leu.2010.143","volume":"24","author":"Y Chen","year":"2010","unstructured":"Chen Y, Peng C, Sullivan C, et al. Critical molecular pathways in cancer stem cells of chronic myeloid leukemia. Leukemia. 2010;24:1545\u201354.","journal-title":"Leukemia"},{"key":"117_CR42","doi-asserted-by":"crossref","first-page":"713","DOI":"10.18632\/oncotarget.333","volume":"2","author":"J-C Chomel","year":"2011","unstructured":"Chomel J-C, Turhan AG. Chronic myeloid leukemia stem cells in the era of targeted therapies: resistance, persistence and long-term dormancy. Oncotarget. 2011;2:713\u201327.","journal-title":"Oncotarget"},{"key":"117_CR43","doi-asserted-by":"crossref","first-page":"6909","DOI":"10.1182\/blood-2010-11-317750","volume":"118","author":"S Hegde","year":"2011","unstructured":"Hegde S, Kaushal N, Ravindra KC, et al. \u039412-prostaglandin J3, an omega-3 fatty acid-derived metabolite, selectively ablates leukemia stem cells inmice. Blood. 2011;118:6909\u201319.","journal-title":"Blood"},{"key":"117_CR44","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1111\/j.1349-7006.2010.01584.x","volume":"101","author":"K Naka","year":"2010","unstructured":"Naka K, Hoshii T, Hirao A. Novel therapeutic approach to eradicate tyrosine kinase inhibitor resistant chronic myeloid leukemia stem cells. Cancer Sci. 2010;101:1577\u201381.","journal-title":"Cancer Sci"},{"key":"117_CR45","doi-asserted-by":"crossref","unstructured":"Cilloni D, Saglio G: Molecular pathways: BCR-ABL. Clin Cancer Res Published OnlineFirst December 8, 2011; doi: 10.1158\/1078-0432.CCR-10-1613 .","DOI":"10.1158\/1078-0432.CCR-10-1613"},{"key":"117_CR46","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/S0140-6736(05)70931-4","volume":"365","author":"M Bocchia","year":"2005","unstructured":"Bocchia M, Gentili S, Abruzzese E, et al. Effect of a p210 multipeptide vaccine associated with imatinib or interferon in patients with chronic myeloid leukaemia and persistent residual disease: a multicenter observational trial. Lancet. 2005;365:657\u201362.","journal-title":"Lancet"},{"key":"117_CR47","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1038\/leu.2009.43","volume":"23","author":"MW Drummond","year":"2009","unstructured":"Drummond MW, Heaney N, Kaeda J, et al. A pilot study of continuous imatinib vs pulsed imatinib with or without G-CSF in CML patients who have achieved a complete cytogenetic response. Leukemia. 2009;23:1199\u2013201.","journal-title":"Leukemia"},{"key":"117_CR48","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1172\/JCI35660","volume":"119","author":"C Bellodi","year":"2009","unstructured":"Bellodi C, Lidonnici MR, Hamilton A, et al. Targeting autophagy potentiates tyrosine kinase inhibitor-induced cell death in Philadelphia chromosome-positive cells, including primary CML stem cells. J Clin Invest. 2009;119:1109\u201323.","journal-title":"J Clin Invest"},{"key":"117_CR49","doi-asserted-by":"crossref","first-page":"5321","DOI":"10.1200\/JCO.2010.27.9943","volume":"28","author":"JA Low","year":"2010","unstructured":"Low JA, de Sauvage FJ. Clinical experience with Hedgehog pathway inhibitors. J Clin Oncol. 2010;28:5321\u20136.","journal-title":"J Clin Oncol"},{"key":"117_CR50","doi-asserted-by":"crossref","first-page":"2511","DOI":"10.1056\/NEJMoa1004095","volume":"363","author":"C Preudhomme","year":"2010","unstructured":"Preudhomme C, Guilhot J, Nicolini FE, et al. Imatinib plus peginterferon alfa-2a in chronic myeloid leukemia. New Engl J Med. 2010;363:2511\u201321.","journal-title":"New Engl J Med."},{"key":"117_CR51","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1038\/nm.1973","volume":"15","author":"T Sato","year":"2009","unstructured":"Sato T, Onai N, Yishihara H, et al. Interferon regulatory factor-2 protects quiescent hematopoietic stem cells from type I interferon-dependent exhaustion. Nat Med. 2009;15:696\u2013700.","journal-title":"Nat Med"},{"key":"117_CR52","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1038\/nature07815","volume":"458","author":"MAG Essers","year":"2009","unstructured":"Essers MAG, Offner S, Blanco-Bose WE, et al. IFN\u03b1 activates dormant haematopoietic stem cells in vivo. Nature. 2009;458:904\u20138.","journal-title":"Nature"},{"key":"117_CR53","doi-asserted-by":"crossref","first-page":"4179","DOI":"10.1182\/blood-2010-12-325373","volume":"118","author":"S Bhattacharya","year":"2011","unstructured":"Bhattacharya S, Zheng H, Tzimas C, et al. Bcr-abl signals to desensitize chronic myeloid leukemia cells to IFN\u03b1 via accelerating the degradation of its receptor. Blood. 2011;118:4179\u201387.","journal-title":"Blood"}],"container-title":["Current Hematologic Malignancy Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11899-012-0117-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11899-012-0117-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11899-012-0117-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,4]],"date-time":"2020-07-04T02:29:33Z","timestamp":1593829773000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11899-012-0117-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,3,13]]},"references-count":53,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2012,6]]}},"alternative-id":["117"],"URL":"https:\/\/doi.org\/10.1007\/s11899-012-0117-2","relation":{},"ISSN":["1558-8211","1558-822X"],"issn-type":[{"value":"1558-8211","type":"print"},{"value":"1558-822X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,3,13]]}}}